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Kathryn B. Garber1,*Mutation-Specific Therapy for Cystic Fibrosis
Although DF508 is the classic cystic fibrosis mutation,
there is great mutational diversity among patients with
this disorder. The shared consequence of these mutations
is a loss of CFTR function, but whereas some mutations
lead to a complete lack of the protein, others yield a protein
that doesn’t conduct Cl properly. One therapeutic
strategy is to try to tweak additional activity out of the
nonfunctional channels, although this approach is only
relevant for the reduced function, and not the null muta-
tions. Ramsey et al. recently reported the results of a phase
III randomized, double-blind, placebo-controlled trial
using such a strategy with a drug called ivacaftor (VX-
770), which is a CFTR potentiator that is designed to
increase the time that activated CFTR Cl channels remain
open. The trial was exclusive to CF patients who had at
least one copy of the G551D CFTR mutation, because
this is the most common CFTR mutation that yields cell-
surface but nonfunctional CFTR protein. Treatment in
these patients yielded weight gain, improved pulmonary
function, and decreased hospitalizations due to pulmo-
nary exacerbations while not leading to adverse events.
This is also the first drug shown to reduce sweat
Cl measurements below the diagnostic threshold of
60 mmol/L for CF. Unfortunately, only approximately
5% of CF patients carry a G551D mutation, but it may be
that ivacaftor is beneficial for patients with other similar
mutations, including the common DF508, which yields
some CFTR—albeit in greatly reduced amount—at the
cell surface.
Ramsey et al. NEJM 365: 1663–1672.
New and Better?
What makes humans human? Although our genomes are
99% similar to chimpanzees at a DNA sequence level, key
genetic changes must have given rise to the features that
make us so different from our next-closest relatives. To
find some of these changes, Wu et al. used a bioinformatics
approach designed to find genes that arose de novo in hu-
mans. They found 60 new protein-coding genes that are
not present in primates; 59 of these are fixed in the human
population. Publicly available RNA-seq data suggest that
these novel genes tend to be most highly expressed in
the cerebral cortex, an intriguing finding that could lead
to discoveries into the increased cognitive ability of hu-
mans compared to our primate relatives.1Department of Human Genetics, Emory University School of Medicine, Atlan
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Get Moving
Can exercise overcome a severe genetic mutation? It may
seem like a crazy idea, but in some sense it works. Fryer
et al. recently asked whether regular exercise could alter
the disease course in a mouse model of spinocerebellar
ataxia type 1, a progressive neurodegenerative disorder.
When exercised on a rotarod apparatus several times a
week, the life spans of these mice increased substantially.
At the same time, exercise increased the expression of
epidermal growth factor (EGF), which in turn decreased
expression of Capicua, a transcriptional repressor. Capicua
appears central to the improvements in life span; the
authors also found that SCA1 mice bred to have 50%
reductions in Capicua live longer than their SCA1 counter-
parts. Regardless of mechanism, it is intriguing that exer-
cise may improve outcomes in people with SCA1. A second
recent paper identified another growth factor as key in
SCA1. Cvetanovic et al. used another mouse model of
SCA1 to demonstrate that the mutant protein ATXN1
represses expression of vascular endothelial growth factor
(VEGF). They proposed that cerebellar dysfunction in
SCA1may at least partially result from decreased angiogen-
esis due to reduced VEGF, and, in fact, infusion of VEGF
into the brains of SCA1 mice improved their motor perfor-
mance.
Fryer et al. Science 334: 690–693.
Cvetanovic et al. Nature Medicine 17: 1445–1447.
An Unwanted Complement
Variation in CFH conferring risk of age-related macular
degeneration (AMD) is one of the strongest genetic risk
factors yet identified for a complex trait via genetic associ-
ation studies. The common Y402H substitution and an
intronic SNP in CFH together explain a substantial fraction
of AMD in the population. Although this defines a sig-
nificant contribution to genetic risk of AMD, Raychaud-
huri et al. wondered whether additional, rare variation in
the same gene might tell us more about its role in the
disease. They defined a risk haplotype in CFH through
use of a high-density genetic association study and then
identified a putative culprit on the haplotype via DNA
sequencing. The variant they discovered, R1210C, is a
highly penetrant risk variant for AMD that is associatedta, GA 30322, USA
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with an earlier-than-normal onset of disease. Whereas the
rare, high-risk variantmay havemore relevance on an indi-
vidual basis and the common, lower-risk variant is more
important for risk of AMD on a population level, it is the
combination that better defines the role of CFH in risk of
AMD. Although few clear examples exist beyond this
one, it is likely that for other complex traits, a combination
of rare and common variation in the same genes will
contribute to the genetic liability for disease.
Raychaudhuri et al. Nature Genetics. Published online
October 23, 2011. 10.1038/ng.976.
New Role Discovered for Argininosuccinate Lyase
in NO Production
Although controlling hyperammonemia to avoid its
neurotoxic effects is crucial to the management of the
urea cycle disorder argininosuccinate lyase (ASL) defi-
ciency, even individuals who are under tight metabolic
control can still have multiorgan disease that includes686 The American Journal of Human Genetics 89, 685–686, Decembintellectual impairment, progressive liver disease, and
hypertension. These features make ASL deficiency unique
among the urea cycle disorders, although the reason
behind this difference has been unclear. Because the citrul-
line cycle, of which ASL is a part, produces nitric oxide
(NO), Erez et al. suspected that NO deficiency might be
the root of the problem. This did, in fact, turn out to be
the case: in experiments in humans and mice, they found
that ASL deficiency leads to reduced NO levels, but not
simply due to reduced catalytic activity of ASL. In addition
to its role in the citrulline-NO cycle, they discovered a
structural role for ASL in the assembly of the NO synthase
complex. In mice with reduced amounts of Asl, adminis-
tration of nitrite, which can be converted to NO, extends
their life span and normalizes their blood pressure,
opening a potential avenue for management of individuals
with ASL deficiency.
Erez et al. Nature Medicine. Published online November 13,
2011. 10.1038/nm.2544.This Month in Our Sister JournalsAlone or Together
Simply finding two sequence changes in the relevant gene
does not necessarily diagnose an autosomal-recessive
condition, because basic Sanger sequencing approaches
cannot distinguish cis and trans configurations of muta-
tions. If both changes are actually on the same allele, the
individual in question might have one normal copy of
the gene and therefore be an unaffected carrier of the
disease. The traditional method of determining the config-
uration of mutations is to test parents and confirm that
each parent carries one of the two mutations. What to do
when parents aren’t available or when a de novo mutation
is at play? Chen and Schrijver developed a digital PCR
method to distinguish mutation configuration for two
segments of the genome. For variation in GJB2 that leads
to hearing impairment, they confirm in eight samples
that p.Val27Ile and p.Glu114Gly occur in cis, which is
believed to be the pathogenic configuration. They also
developed an assay to assess the configuration in CFTR of
p.Arg117His and the allele at an intron 8 poly T tract
that determines its pathogenicity. They propose that
similar digital PCRs could be developed to assess fairlycommon sequence changes whose pathogenicity is depen-
dent on their configuration.
Chen and Schrijver. Genetics in Medicine. 10.1097/GIM.
0b013e3182272e0b.
Nurture Adds to Nature
So far, we haven’t been able to completely explain the
underlying genetic variation that governs complex human
diseases, a problem that has been dubbed the missing heri-
tability problem. Furrow et al. wondered whether environ-
mentally triggered epigenetic modification contributes to
the missing heritability, and they developed models to
see whether this is the case. In fact, they did find evidence
that epigenetic variation could underlie a good deal of the
trait correlation between relatives. Even in the absence of
a genetic contribution to a trait, they found that there
can be good phenotypic correlation between relatives.
Thus, their models suggest that not only nature but also
nurture—in other words, environment—could contribute
a substantial fraction to the heritability of complex traits.
Furrow et al. Genetics. Published online October 3, 2011.
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